Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2014-06-10 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 10, 2014, announcing that BioAlliance Pharma has secured an extended patent protection for its drug Livatag® in Japan until 2032. This announcement relates to intellectual property rights and corporate strategy regarding a specific drug program. It is not a full annual report (10-K), an earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a proxy statement. It is an announcement concerning corporate development and intellectual property, which fits best under general corporate news or potentially a specific IP/Legal update. Since there is no specific code for 'Intellectual Property Update' and it is not a legal proceeding (LTR), the most appropriate general category for significant corporate news that isn't explicitly covered by other codes (like M&A, Financing, or Dividend) is the general Regulatory Filings/Announcements category (RNS). However, given the content is a specific corporate update about patent strength, it is a form of corporate information release. Since the document is a press release detailing a specific corporate event (patent grant), and it is not a financial report, a management discussion, or a shareholder vote result, RNS (Regulatory Filings/Miscellaneous Announcement) serves as the best fit among the provided options for a non-standard corporate update.
2014-06-10 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital au 31 mai 2014" (Information relating to the total number of voting rights and shares comprising the capital as of May 31, 2014). It explicitly references compliance with the French Commercial Code (Article L. 233-8 II) and the AMF General Regulation (Article 223-16), which mandates the publication of the total number of voting rights monthly. This specific type of mandatory disclosure, detailing share capital and voting rights, is a standard regulatory filing in France. While it is a specific regulatory disclosure, it does not fit perfectly into the provided codes like 10-K, ER, or IR. It is a mandatory regulatory announcement concerning capital structure/voting rights. Given the options, it is a specific regulatory filing. Since there isn't a dedicated 'Voting Rights Disclosure' code, and it is a formal regulatory announcement, it falls best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). However, since it is a routine monthly disclosure of voting rights rather than a change in the number of shares issued (SHA), RNS is the most appropriate general regulatory fallback category for mandatory, non-periodic financial reports.
2014-06-10 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document explicitly states it is a 'Disclosure of total number of voting rights and number of shares in the capital' as of a specific date (May 31, 2014), referencing French commercial code and AMF regulations. This type of filing, which reports the total outstanding shares and voting rights, is a specific regulatory disclosure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for reporting the total number of voting rights, even though it is not the result of a specific vote, but rather a mandatory periodic disclosure of the capital structure for voting purposes. It is not an AGM result (AGM-R), nor a general regulatory filing (RNS) if a more specific category exists. Since it deals directly with voting rights disclosure, DVA is selected.
2014-06-10 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
M&A Activity Classification · 99% confidence The document is titled "TRAITE DE FUSION DEFINITIF ENTRE BIOALLIANCE PHARMA ET TOPOTARGET" (Definitive Merger Agreement between BioAlliance Pharma and Topotarget) and details the terms, exchange ratio, governance changes, and timeline for the merger of two companies, resulting in a new entity named Onxeo. This content explicitly describes a significant corporate transaction involving the combination of two entities, which falls under the category of Mergers & Acquisitions (M&A) activity. The appropriate code is TAR (M&A Activity). The document is a detailed agreement, not just a brief announcement of a report (ruling 2 does not apply).
2014-05-21 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
M&A Activity Classification · 99% confidence The document text explicitly announces the 'DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET' and details the exchange ratio, shareholder votes required, and the resulting new entity 'ONXEO'. It confirms the terms announced previously and outlines the definitive steps, including the need for shareholder votes at extraordinary general meetings on specific dates (June 27 and June 30, 2014). This content strongly indicates a major corporate transaction announcement, specifically a merger or takeover proposal. Based on the provided definitions, the most appropriate classification is 'M&A Activity' (Code: TAR). Although it mentions shareholder votes, the primary focus is the merger agreement itself, not just the voting results (DVA) or a general regulatory filing (RNS).
2014-05-21 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 19, 2014, announcing that Livatag® (doxorubicin Transdrug™) received 'Fast Track' status from the FDA for treating hepatocellular carcinoma. It details the significance of this regulatory designation, provides clinical trial updates (Phase III enrollment), and includes forward-looking statements and boilerplate information about the company (BioAlliance Pharma SA). This type of announcement, focusing on a specific regulatory milestone or clinical development update outside of routine financial reporting (like 10-K or ER), is best classified as a general regulatory announcement or news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific insider transaction (DIRS), the most appropriate general category for significant, non-financial corporate news is Regulatory Filings (RNS), as it communicates material information to the market that doesn't fit the other specific codes. It is not a Report Publication Announcement (RPA) because it is the news itself, not an announcement *about* the publication of another report.
2014-05-19 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.